New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
07:44 EDTMRNS, LGNDMarinus Pharmaceuticals enters into agreement with CyDex Pharmaceuticals
Marinus Pharmaceuticals (MRNS) announced that it has entered into an agreement with CyDex Pharmaceuticals, a wholly owned subsidiary of Ligand Pharmaceutical (LGND), for the clinical use of Captisol, a patent protected, uniquely modified cyclodextrin, whose chemical structure was designed to improve solubility, stability, bioavailability and dosing of active pharmaceutical ingredients. Marinus intends to evaluate optimizing its intravenous dose form of ganaxolone with Captisol.
News For MRNS;LGND From The Last 14 Days
Check below for free stories on MRNS;LGND the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 10, 2014
15:42 EDTMRNSFranklin Resources reports 10.2% passive stake in Marinus Pharmaceuticals
Subscribe for More Information
September 9, 2014
09:58 EDTLGNDLigand management to meet with Craig Hallum
Meeting to be held in Milwaukee on September 15 hosted by Craig Hallum.
08:32 EDTLGNDLigand expands license agreement with CURx for Lamotrigine program
Subscribe for More Information
07:19 EDTMRNSMarinus Pharmaceuticals initiated with an Outperform at Oppenheimer
Target $12.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use